NCE-1 Intelligence & Market Opportunity

Iqirvo

Elafibranor

Hepatoprotective Agents

Oral Tablets

Iqirvo is used with ursodeoxycholic acid to treat primary biliary cholangitis. It works by targeting key pathways in the liver, including PPAR alpha and PPAR delta.

Approval Date

10-Jun-24

NCE-1 Date

10-Jun-28

NCE Date

10-Jun-29

Commercial snapshot

Market performance & projections

Revenue ($M)

233

CAGR (%)

0.3165

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

368

2027

499

2028

604

2029

700

2030

801

2031

871

2032

898

Molecule profile

Details & specifications

Molecule

Elafibranor

Innovator

IPSEN BIOPHARMACEUTICALS INC

Dosage Form

Oral Tablets

Strength

80 mg

Therapeutic Category

Hepatoprotective Agents

Usage

To treat primary biliary cholangitis in combination with ursodeoxycholic acid

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.